Printer Friendly

FMPI ANNOUNCES ORDER OF 27 EECP TREATMENT DEVICES TO OPEN FIRST OF 12 PLANNED CLINICS

 FMPI ANNOUNCES ORDER OF 27 EECP TREATMENT DEVICES
 TO OPEN FIRST OF 12 PLANNED CLINICS
 HAUPPAUGE, N.Y., July 28 /PRNewswire/ -- Future Medical Products, Inc., (NASDAQ: FMPI) announced today its decision to open the first of 12 planned outpatient therapy centers utilizing its proprietary Enhanced External Counter Pulsation (EECP) device to treat coronary artery disease non-invasively.
 FMPI signed an option agreement to purchase an approximate 10,000 square feet facility near Stony Brook Hospital and has placed an order for 27 EECP treatment devices. Steven Cantor, president, stated "recent scientific reports have generated an overflow of calls from physicians and patients requesting treatment. This new center will allow us to treat up to 1500 patients per year." The patient cost for a full course of therapy is only $6,000 which is approximately 20 percent of the cost of coronary bypass surgery. The company has secured adequate sources of financing to fund the project.
 Future Medical Products, Inc. is a medical technology company involved in the research, development and distribution of healthcare products.
 -0- 7/28/92
 /CONTACT: Herb Glicksman of Future Medical Products, 516-348-0500/
 (FMPI) CO: Future Medical Products Inc. ST: New York IN: HEA SU:


LR-SM -- NY012 -- 3884 07/28/92 09:11 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 28, 1992
Words:206
Previous Article:SPEAR FINANCIAL ANNOUNCES SECOND QUARTER EARNINGS UP 71 PERCENT, YEAR-TO-DATE UP 116 PERCENT
Next Article:MONRO MUFFLER BRAKE, INC. REPORTS FIRST QUARTER SALES UP 11.4 PERCENT AND NET INCOME UP 9.4 PERCENT
Topics:


Related Articles
FUTURE MEDICAL PRODUCTS, INC. ESTABLISHES OPERATING COMPANY WITH IMMEDIATE REVENUE
FUTURE MEDICAL PRODUCTS ANNOUNCES A PRIVATE PLACEMENT TRANSACTION AND THE ISSUANCE OF PREFERRED STOCK
FUTURE MEDICAL PRODUCTS ANNOUNCES THE APPOINTMENT OF THREE NEW DIRECTORS AND TWO NEW EXECUTIVES
FUTURE MEDICAL PRODUCTS ANNOUNCES THE ACQUISITION OF VASOGENICS
FUTURE MEDICAL PRODUCTS ANNOUNCES FDA MARKETING CLEARANCE OF EECP
NONINVASIVE THERAPY FOR ANGINA PATIENTS PRESENTED AT AMERICAN COLLEGE OF CARDIOLOGY
STUDY SHOWS NON-INVASIVE TREATMENT HELPS ANGINA PATIENTS WHEN MEDICAL AND SURGICAL TREATMENTS FAIL
Non-Surgical Treatment Can Offer Sustained Relief From Chest Pain
First Results of Vasomedical's EECP Heart Failure Study.
Mayo Clinic Physicians Confirm Positive Early Results With Enhanced External Counterpulsation.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters